Hypericum perforatum L. and the Underlying Molecular Mechanisms for Its Choleretic, Cholagogue, and Regenerative Properties
-
Published:2023-06-15
Issue:6
Volume:16
Page:887
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Mohagheghzadeh Ala1, Badr Parmis2, Mohagheghzadeh Abdolali23, Hemmati Shiva145ORCID
Affiliation:
1. Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran 2. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran 3. Department of Phytopharmaceuticals (Traditional Pharmacy), School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran 4. Biotechnology Research Center, Shiraz University of Medical Sciences, Shiraz 71468-64685, Iran 5. Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University, Cheras, Kuala Lumpur 56000, Malaysia
Abstract
Any defects in bile formation, secretion, or flow may give rise to cholestasis, liver fibrosis, cirrhosis, and hepatocellular carcinoma. As the pathogenesis of hepatic disorders is multifactorial, targeting parallel pathways potentially increases the outcome of therapy. Hypericum perforatum has been famed for its anti-depressive effects. However, according to traditional Persian medicine, it helps with jaundice and acts as a choleretic medication. Here, we will discuss the underlying molecular mechanisms of Hypericum for its use in hepatobiliary disorders. Differentially expressed genes retrieved from microarray data analysis upon treatment with safe doses of Hypericum extract and intersection with the genes involved in cholestasis are identified. Target genes are located mainly at the endomembrane system with integrin-binding ability. Activation of α5β1 integrins, as osmo-sensors in the liver, activates a non-receptor tyrosine kinase, c-SRC, which leads to the insertion of bile acid transporters into the canalicular membrane to trigger choleresis. Hypericum upregulates CDK6 that controls cell proliferation, compensating for the bile acid damage to hepatocytes. It induces ICAM1 to stimulate liver regeneration and regulates nischarin, a hepatoprotective receptor. The extract targets the expression of conserved oligomeric Golgi (COG) and facilitates the movement of bile acids toward the canalicular membrane via Golgi-derived vesicles. In addition, Hypericum induces SCP2, an intracellular cholesterol transporter, to maintain cholesterol homeostasis. We have also provided a comprehensive view of the target genes affected by Hypericum’s main metabolites, such as hypericin, hyperforin, quercitrin, isoquercitrin, quercetin, kaempferol, rutin, and p-coumaric acid to enlighten a new scope in the management of chronic liver disorders. Altogether, standard trials using Hypericum as a neo-adjuvant or second-line therapy in ursodeoxycholic-acid-non-responder patients define the future trajectories of cholestasis treatment with this product.
Funder
Shiraz University of Medical Sciences
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference181 articles.
1. Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer;Li;Adv. Pharmacol.,2015 2. Bile acid nuclear receptor FXR and digestive system diseases;Ding;Acta Pharm. Sin. B,2015 3. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response;Cai;JCI Insight.,2017 4. Wu, H., Chen, C., Ziani, S., Nelson, L.J., Ávila, M.A., Nevzorova, Y.A., and Cubero, F.J. (2021). Fibrotic Events in the Progression of Cholestatic Liver Disease. Cells, 10. 5. Pharmacological interventions for primary biliary cholangitis: An attempted network meta-analysis;Saffioti;Cochrane Database Syst. Rev.,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|